Vijay Kumar

“I guess my first question, Matt, I think you made some helpful comments here on the fiscal 27 uh framework i'm curious when i when i look at your bio processing segments uh came in you know quite solid here in 3q uh and you have a few moon pieces in the 27 the instrument orders have been quite solid here uh…”

“Maybe I'll focus one on the big picture. There's been concerns around utilization environment in a CapEx environment. When I look at your APM business, I mean, that seems to be humming, double data trades.”

“I just want to make sure we understand the dual rationale. This feels like a dual product strategy, right, with an MCT. and I know you have a 2.0 product that's going to address the other part of the market.”

“I guess I'll focus on bone tech in Simmon, north of 20%, really strong. How much of this is being driven by Simmer's tech strategy resonating in the marketplace versus any one-timer trade?”

“I guess my first one is on the updated guidance here at LOOP. So your clinical volumes, I think, implied for back half is 23%. And what drives this acceleration from first half?”